FoundationOne Liquid CDx
Foundation Medicine, Inc. · Decision date May 27, 2026
What did the FDA approve?
FDA records P190032/S029 as a supplement to PMA P190032, with the supplement type “Panel Track”. The recorded decision is approval, dated May 27, 2026.
FDA approval order statement
Approval order to expand the intended use of FoundationOne Liquid CDx (F1LCDx) to include a companion diagnostic indication for the detection of HRR gene alterations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) in patients with metastatic castrate-resistant prostate cancer (mCRPC) who may benefit from treatment with TALZENNA (talazoparib) in combination with XTANDI (enzalutamide).
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Pathology
- Decision date
- May 27, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190032/S029
- Regulatory pathway
- PMA supplement
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- May 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190032 · Original PMA
FoundationOne Liquid CDx (F1 Liquid CDx)
P190032/S029 received
Application receipt date recorded by FDA.
P190032/S025 · Related supplement
FoundationOneLiquid CDx
P190032/S029 · FDA decision
Panel Track
P190032/S030 · Related supplement
FoundationOne Liquid CDx (F1 Liquid CDx)
P190032/S032 · Related supplement
FoundationOne Liquid CDx (F1LCDx)
Timeline entries are records held by MedtechLedger for P190032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Foundation Medicine, Inc. | PMA approval | Aug 26, 2020 | FDA | |
FoundationOneLiquid CDxP190032/S025 | Foundation Medicine, Inc. | PMA supplement | May 8, 2026 | FDA |
FoundationOne Liquid CDx (F1 Liquid CDx)P190032/S030 | Foundation Medicine, Inc. | PMA supplement | Aug 12, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Foundation Medicine, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 400 Summer St., Boston, MA, 02210
Sources and methodology
- Original FDA record: P190032/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





